DreamJay
Delivers dream induction technology for entertainment and better health.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
* | $2.3m | Series A | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | (55 %) |
| EBITDA | 0000 | 0000 |
| % EBITDA margin | 14 % | 16 % |
| Profit | 0000 | 0000 |
| % profit margin | 12 % | 15 % |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Operating from both Warsaw, Poland, and San Francisco, USA, DreamJay is a health technology company established in 2014 with a focus on addressing sleep disorders through its mobile application, Nightly. The company was co-founded by Michael Wolniak, who serves as Chairman and has a background in digital business strategy, and Lukasz Mlodyszewski, the CEO, who is an entrepreneur with venture capital experience and an alumnus of Singularity University.
DreamJay's core product, the Nightly app, is designed for individuals experiencing sleep difficulties. It aims to facilitate faster sleep onset, mitigate bad dreams, and decrease nocturnal awakenings. The application employs a combination of audio-visual stimulation and proprietary algorithms to actively monitor a user's sleep. Before sleeping, the user interacts with a brief, calming audio-visual theme. The app then tracks sleep patterns using the phone's sensors, and at critical moments, it introduces gentle, soothing sounds to maintain an uninterrupted state of rest and prevent awakenings.
The development of Nightly involved a multidisciplinary team of scientists, designers, and entrepreneurs, with its scientific underpinning validated in studies at the Sleep Disorders Center at the Institute of Psychiatry and Neurology in Warsaw. In September 2017, DreamJay secured a significant milestone with a $2.3 million Series A funding round. The investment was led by the Joint Polish Investment Fund (JPIF), a major life science venture capital fund in Poland, with contributions from the Swedish fund Nordic Makers and other private investors. This capital was earmarked for further clinical research and development, with the strategic goal of pursuing premarket review from the U.S. Food and Drug Administration (FDA).
Keywords: sleep technology, digital therapeutics, mobile health, sleep disorders, insomnia treatment, nightmare reduction, sleep monitoring, healthtech, Warsaw startup, AI sleep app, audio-visual stimulation, sleep science, venture capital, Series A, clinical validation, FDA submission, Michael Wolniak, Lukasz Mlodyszewski